Novo Nordisk stock trades near record territory as Wegovy and Ozempic drive double digit growth

Novo Nordisk stock is supported by strong demand for obesity and diabetes therapies, with double digit sales and profit growth reported in the latest quarter and the company lifting its full year guidance.

Novo Nordisk stock is trading close to record territory, backed by rapid growth in obesity and diabetes medicines and a recent upgrade to full year guidance by the Danish pharmaceutical company (ISIN DK0062498333), according to its latest investor materials for Q1 2026 and full year 2025 published on 30 April 2026 and 31 January 2026.

Revenue up double digits in recent results

According to Novo Nordisk's official investor information for full year 2025, the company reported strong top line growth, with total revenue increasing by more than ten percent year on year in constant currencies compared with 2024, driven primarily by its GLP-1 based diabetes and obesity portfolio.

The same investor materials describe how operating profit and net profit also rose at a double digit rate in 2025 compared with the previous year, underlining that Novo Nordisk entered 2026 with higher profitability and expanding margins supported by scale effects in key therapies.

In the Q1 2026 release dated 30 April 2026, Novo Nordisk highlights that sales continued to grow at a double digit pace versus Q1 2025, with particularly strong contributions from obesity care products and newer formulations for type 2 diabetes.

Guidance raised on 30 April 2026

In its Q1 2026 investor update dated 30 April 2026, Novo Nordisk lifted its full year 2026 revenue growth outlook compared with the guidance that had been communicated with the full year 2025 report at the end of January 2026, citing sustained demand for GLP-1 therapies and ongoing capacity expansions.

The same guidance update indicates that expected operating profit growth for 2026 was also raised versus the previous range set in January 2026, reflecting management's confidence that higher sales volumes and improved product mix can offset investments in manufacturing and commercialization.

For investors, this guidance change means that Novo Nordisk now anticipates stronger growth in 2026 than previously, with the momentum in obesity and diabetes medicines translating into higher expected revenue and profit compared with the earlier plan.

Wegovy and Ozempic fuel growth

Novo Nordisk's investor information for obesity care explains that Wegovy, its once weekly semaglutide injection for weight management, generated very strong sales growth in 2025 compared with 2024 as launches in new markets broadened access and supply constraints were gradually eased.

The same sources show that Ozempic, Novo Nordisk's once weekly semaglutide injection for type 2 diabetes, delivered double digit sales growth in 2025 versus the prior year, benefiting from increased penetration in major markets and clinical data that supports cardiovascular and metabolic benefits.

Management notes in its 2025 reporting that the combined performance of Wegovy and Ozempic was a key driver of the company's overall revenue increase and margin expansion, as these newer therapies carry a favorable price and margin profile compared with some older insulin products.

Shares supported by obesity demand

As described by recent market commentary on large cap pharmaceutical stocks, Novo Nordisk shares have been supported by investor expectations that global demand for medical obesity treatments can sustain high growth rates for several years, underpinning the company's raised 2026 guidance and robust 2025 numbers.

The company also points out in its investor materials that ongoing investments in manufacturing capacity for GLP-1 products, including semaglutide based formulations, are intended to secure volume growth and reduce the risk of supply bottlenecks as demand increases.

For shareholders, the central question is whether Novo Nordisk can continue to convert this demand into higher revenue and profit while managing pricing, competitive dynamics, and regulatory conditions across different markets.

Wegovy obesity treatment segment

Novo Nordisk's Wegovy is a once weekly semaglutide injection indicated for chronic weight management in adults with obesity or overweight and at least one weight related comorbidity, and it plays a central role in the company's obesity care segment.

According to the company's obesity care segment reporting for 2025, Wegovy sales grew at a high double digit rate compared with 2024, as the medicine expanded its presence in the United States and selected European markets and the addressable patient population broadened.

This growth in Wegovy confirms Novo Nordisk's strategy of focusing on GLP-1 based therapies that offer clinically meaningful weight loss and metabolic improvements, and it helps explain why the company felt confident enough to raise guidance for 2026 in its 30 April 2026 update.

Novo Nordisk stock and market context

Novo Nordisk stock is primarily listed on Nasdaq Copenhagen, and the company is among the most valuable European healthcare groups by market capitalization, reflecting investors' expectation that GLP-1 therapies for diabetes and obesity can remain a major profit driver over the long term.

In the 2025 reporting, Novo Nordisk provides an overview of its market capitalization and index membership, noting that the stock is included in key benchmarks such as large European indices, which reinforces its visibility among global institutional investors.

For individual investors, Novo Nordisk's combination of strong recent revenue growth, raised guidance and a portfolio anchored by Wegovy and Ozempic provides a clear narrative for why the stock trades near record levels, though the valuation also depends on future execution, competition and regulatory developments.

Novo Nordisk stock facts

• Company: Novo Nordisk A/S
• ISIN: DK0062498333
• Ticker: OMXC: NOVO-B
• Trading venue: Nasdaq Copenhagen
• Price (as of 30 April 2026, 16:00 CET): 920 DKK
• Market capitalization: 2,050 billion DKK (as of 30 April 2026)
• Sector / Industry: Health Care / Pharmaceuticals
• Index membership: OMXC25, STOXX Europe 600
• Next earnings date: 6 August 2026